Tazemetostat is mainly used to treat follicular lymphoma and epithelioid sarcoma with specific gene mutations, and its efficacy is closely related to genetic testing results. Discontinuation of medication should be gradually carried out based on efficacy evaluation and adverse reaction grading, and special attention should be paid to subsequent monitoring. The following is a detailed explanation about the treatment effect and precautions for stopping medication.

1. Treatment effect

(1) Follicular lymphoma: The objective response rate (ORR) for EZH2 mutant patients can reach 69%, while for wild-type patients it is 35%, with a median response duration of approximately 11 months.

(2) Epithelioid sarcoma: The overall ORR is 15%, with 6% achieving complete remission and a median progression free survival of 5.5 months.

2 Discontinuation criteria

(1) Disease progression: Treatment should be terminated after tumor progression is confirmed by imaging.

(2) Intolerable toxicity: If there is grade 4 hematological toxicity or grade 3 or above non hematological toxicity, the medication must be permanently discontinued.

(3) Patient willingness: When the patient requests to stop treatment, they must be fully informed of the risks.

3 Precautions for discontinuation of medication

(1) Gradual reduction: It is recommended to gradually reduce dosage within 2-4 weeks in non emergency situations to avoid sudden discontinuation of medication.

(2) Adverse reaction monitoring: After discontinuing the medication, it is still necessary to continue monitoring the original adverse reactions for at least 3 months.

(3) Subsequent treatment linkage: Alternative treatment plans need to be planned in advance to avoid treatment vacuum periods.

4 Special populations stop taking medication

(1) Liver dysfunction: Children Pugh B/C grade patients should immediately discontinue medication.

(2) Women of childbearing age: Continue contraception for 6 months after discontinuing medication.

(3) Elderly patients: Need to closely monitor changes in their physical condition after discontinuing medication.

5 Special Precautions

(1) Transportation requirements: Temperature must be monitored during cold chain transportation, and thawed drugs must not be refrigerated again.

(2) Appearance inspection: Before use, it is necessary to check whether the physical properties of the tablets have changed, such as discoloration or fragmentation.